Opus Genetics (IRD) Common Equity (2010 - 2026)

Opus Genetics (IRD) has 17 years of Common Equity data on file, last reported at -$45.8 million in Q1 2026.

• On a quarterly basis, Common Equity fell 1003.53% year-over-year to -$45.8 million in Q1 2026; TTM through Mar 2026 was -$45.8 million, a 1003.53% decrease from a year earlier, with the FY2025 full-year figure at $15.3 million, up 128.26% from the prior year.
• Common Equity for Q1 2026 stood at -$45.8 million, down from $15.3 million in the prior quarter.
• Over the last five years, Common Equity for IRD reached as high as $50.3 million in Q3 2023 and fell as low as -$45.8 million in Q1 2026.
• Historically, Common Equity has averaged $23.2 million across 5 years, with a median of $17.5 million in 2025.
• Across the five-year window, Common Equity soared 323.36% in 2023 and slumped 1003.53% in 2026, its largest moves.
• Year by year, Common Equity stood at $46.2 million in 2022, then increased by 7.93% to $49.9 million in 2023, then sank by 86.53% to $6.7 million in 2024, then soared by 128.26% to $15.3 million in 2025, then tumbled by 398.64% to -$45.8 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were -$45.8 million in Q1 2026, $15.3 million in Q4 2025, and $6.0 million in Q3 2025.